ABINGDON, OXFORDSHIRE / ACCESSWIRE / May 24, 2022 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces that its Notice of Annual General Meeting ("AGM") was posted to shareholders yesterday, along with the Annual Report for the year ended 31 December 2021. The documents are also available in the "Investors" section of the Company's website at www.midatechpharma.com/financial-reports-accounts.
While the Company will hold the 2022 AGM at its offices at 2.00pm at 1 Caspian Point, Caspian Way, Cardiff CF10 4DQ on 20 June 2022, shareholders may not wish to attend the AGM in person but instead be represented by the Chair of the AGM acting as their proxy. Shareholders may participate, but not vote, in the AGM via Zoom by contacting Sara Siddall at [email protected] who will provide details on how to join the Zoom call. Further details on how to vote by proxy are set out in the Notice of AGM.
For more information, please contact:
| Midatech Pharma PLC |
| Stephen Stamp, CEO, CFO |
| Tel: +44 (0)29 2048 0180 |
| www.midatechpharma.com |
| Strand Hanson Limited (Nominated and Financial Adviser) |
| James Dance / Matthew Chandler / Rob Patrick |
| Tel: +44 (0)20 7409 3494 |
| Turner Pope Investments (TPI) Limited (Broker) |
| Andrew Thacker / James Pope (Corporate Broking) Tel: +44(0)20 3657 0050 |
| IFC Advisory Limited (Financial PR and UK Investor Relations) |
| Tim Metcalfe / Graham Herring |
| Tel: +44 (0)20 3934 6630 |
| Email: [email protected] |
| Edison Group (US Investor Relations) Alyssa Factor Tel: +1 (860) 573 9637 Email: [email protected] |
About Midatech Pharma PLC Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on 'Making Medicines Better' by improving delivery of drugs in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment for life threatening diseases. The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform: · Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months). · MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours. · MidaCore™ platform: a leading edge nanotechnology used for targeting medications to sites of disease. By improving bio-delivery and biodistribution of approved existing molecules, Midatech's unique R&D has the potential to make medicines better, lower technical risks, accelerate regulatory approval and route to market, and provide newly patentable products. The platform nature of the technologies allows the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Midatech Pharma PLC